Shots:

• Lineagen to receive $9.6M consisting of 6-167-510 shares of Bionano’s common stock- ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists- genetic counselors- laboratory operations and billing experts- clinical commercialization experts- and payor contracts
• The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s diagnostics services business based on a menu of LDTs and other services performed in a CLIA-certified environment serving a $1B market
• The addition of Lineagen gives Bionano a unique combination of centralized and decentralized solutions for genomics research and clinical genomics to support revenue growth

­ Ref: Businesswire | Image: Arup Laboratories